Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Equivalents: 2010-2021

Historic Cash & Equivalents for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $311.1 million.

  • Neurocrine Biosciences' Cash & Equivalents fell 26.85% to $311.1 million in Q3 2021 from the same period last year, while for Sep 2021 it was $311.1 million, marking a year-over-year decrease of 26.85%. This contributed to the annual value of $190.3 million for FY2020, which is 69.46% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Cash & Equivalents of $311.1 million as of Q3 2021, which was down 15.46% from $368.0 million recorded in Q2 2021.
  • Neurocrine Biosciences' Cash & Equivalents' 5-year high stood at $425.3 million during Q3 2020, with a 5-year trough of $64.1 million in Q1 2017.
  • Its 3-year average for Cash & Equivalents is $249.3 million, with a median of $190.3 million in 2020.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 258.85% in 2017, then plummeted by 58.49% in 2019.
  • Over the past 5 years, Neurocrine Biosciences' Cash & Equivalents (Quarterly) stood at $254.7 million in 2017, then slumped by 44.36% to $141.7 million in 2018, then fell by 20.76% to $112.3 million in 2019, then spiked by 69.46% to $190.3 million in 2020, then dropped by 26.85% to $311.1 million in 2021.
  • Its last three reported values are $311.1 million in Q3 2021, $368.0 million for Q2 2021, and $352.6 million during Q1 2021.